• Publications
  • Influence
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer
TLDR
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. Expand
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
TLDR
The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included. Expand
New guidelines to evaluate the response to treatment in solid tumors
TLDR
This special article proposes a model by which a combined assessment of all existing lesions, characterized by target lesion and nontarget lesions, is used to extrapolate an overall response to treatment, and provides some philosophic background to clarify the various purposes of response evaluation. Expand
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
TLDR
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. Expand
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
TLDR
A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival. Expand
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
TLDR
Impatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs. Expand
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
TLDR
With the present development of various new anticancer agents, it is recommended that alternative formulation approaches should be pursued to allow a better control of the toxicity of the treatment and the pharmacological interactions related to the use of CrEL. Expand
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
CPT-11 belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug of SN-38, which is approximately 100-1000-fold more cytotoxic than the parent drug. CPT-11 has shown a broadExpand
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
TLDR
BKM120, at the maximum-tolerated dose of 100 mg/d, is safe and well tolerated, with a favorable PK profile, clear evidence of target inhibition, and preliminary antitumor activity, and demonstrates feasibility and proof-of-concept of class I PI3K inhibition in patients with advanced cancers. Expand
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
TLDR
If response induction is the only aim of treatment, a daily dose of400 mg of imatinib is sufficient; however, a dose of 400 mg twice a day achieves significantly longer progression-free survival. Expand
...
1
2
3
4
5
...